November 9, 2010 – In an effort to further promote the utility of PET/CT (positron emission tomography/computed tomography) imaging in assessing the effectiveness of oncology treatments, a new quantification tool is available to support PERCIST (PET response criteria in solid tumors). PERCIST provides standard uptake value (SUV)-based metrics to define response criteria designed to complement the standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Since the introduction of PERCIST, Siemens Healthcare Molecular Imaging created a PET/CT quantification tool to aid in the adoption of PERCIST evaluation criteria. Using a consistent PET protocol and fixed small region of interest, Siemens’ quantification tool evaluates the most active region of a metabolically active tumor to minimize statistical variability and offer the most consistent results. Siemens supports industry initiatives with this software tool that will make PERCIST data available and reproducible for every patient, so that these criteria will be clinically adopted and used in the field.

RECIST is a well established set of rules for determining response to therapy for patients. These criteria were formed on the basis of measuring anatomical changes in tumors using CT imaging. Because PET/CT imaging can detect changes to the tumor at the molecular level, thought leaders in the molecular imaging field introduced PERCIST criteria to use together with RECIST.

While RECIST criteria offer quantifiable data in terms of tumor size, the PERCIST quantification tool creates reproducible, objective results based on metabolic information for tumor trending over time to determine the efficacy of treatment. PERCIST criteria allow treatment response to be measured in the absence of anatomic change through the assessment of metabolic activity, often even before anatomical changes take place. The PERCIST quantification tool evaluates and delineates metabolic information from the tumor. The tool uses an algorithm that automatically identifies peak SUV within a volume of interest, rather than the common single-pixel measure of SUVmax. The PERCIST quantification tool offers a more robust metric that is less susceptible to statistical variation and noise.

For more information: www.siemens.com/healthcare


Related Content

News | Digital Pathology

March 11, 2026 — Royal Philips has announced the expansion of its digital pathology portfolio with new cloud-enabled ...

Time March 26, 2026
arrow
News | FDA

March 24, 2026 — MARS Bioimaging, a New Zealand–headquartered medical device company, has received U.S. Food and Drug ...

Time March 25, 2026
arrow
News | FDA

March 20, 2026 — Siemens Healthineers recently announced its Varian TrueBeam radiotherapy systems, which include ...

Time March 24, 2026
arrow
News | Radiology Imaging

March 23, 2026 — Samsung Medison hsa announced that its U.S. medical imaging businesses, previously operating as ...

Time March 23, 2026
arrow
News | Radiology Business

March 1, 2026 — A new study from the Harvey L. Neiman Health Policy Institute found that practice turnover (i.e ...

Time March 19, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | Breast Imaging

March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...

Time March 13, 2026
arrow
News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
News | Enterprise Imaging

Mar. 9, 2026 — GE HealthCare recently announced that View, the viewer within the Genesis Radiology Workspace, has ...

Time March 12, 2026
arrow
News | Lung Imaging

March 11, 2026 — Noah Medical has announced the publication of the MATCH 2 study in the international, peer-reviewed ...

Time March 12, 2026
arrow
Subscribe Now